HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Rigel Pharmaceuticals (NASDAQ:RIGL) and maintained a $15 price target for the company's stock.
December 08, 2023 | 2:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst reaffirms a Buy rating on Rigel Pharmaceuticals with a $15 price target, potentially influencing investor confidence and the stock's performance.
The reiteration of a Buy rating and maintenance of a $15 price target by a reputable analyst could lead to increased investor confidence and a positive short term impact on Rigel Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100